Skip to content
Menu

Wedbush Maintains Outperform on ORIC Pharmaceuticals, Lowers Price Target to $14

Benzinga Newsdesk 3 weeks ago

Analyst RatingsNewsPrice Target

This page contains a summary, not the full article. Continue to benzinga.com to read the original report.

Wedbush analyst David Nierengarten maintains ORIC Pharmaceuticals (NASDAQ:ORIC) with a Outperform and lowers the price target from $17 to $14.

Wedbush analyst David Nierengarten maintains ORIC Pharmaceuticals (NASDAQ:ORIC) with a Outperform and lowers the price target from $17 to $14.

Read at benzinga.com